Market data including bonds and fuel prices
The unskilled workforce in particular will be affected by the steps the country will be compelled to take
A former senior investigator who worked closely with the public protector on the report accused her of watering it down and removing portions
The premier announced her cabinet after a meeting with the ANC’s deployment committee and its alliance partners
Business Day TV speaks to African Rail Industry Association CEO Mesela Nhlapo
Credit bureau sees more defaults ahead as central bank increases interest rates
The improved sentiment is a result of increased merchandise export and import volumes and more new vehicles sold, Sacci report says
Attorney-general Merrick Garland says there is 'substantial public interest in the matter'
Top swimmers have a rivalry that could develop into one of SA sport’s greatestt
The Italian SUV outguns the Bentley Bentayga's record
Bengaluru — Shares of India’s Panacea Biotec climbed as much as 9% in early trade on Monday, a day after the biotech company said it had received a manufacturing licence for the Sputnik V vaccine.
India has shifted its focus to mass immunisations as experts warn of a looming third wave of the coronavirus pandemic as the country slowly reopens and a new variant, locally called the Delta Plus, emerges.
By July 2, 6% of all eligible adults in India had been inoculated with the two mandatory doses, data from the government’s Co-Win portal showed.
The official coronavirus death toll topped 400,000 last week, though experts say the actual number could have reached one million or even higher.
India is the world’s second-worst coronavirus-hit country after the US.
Panacea Biotec said on Sunday the Indian drugs regulator granted the licence after the company’s collaboration with the Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund that markets the shot internationally.
The licence is for batches of Sputnik V produced at its facilities at Baddi, Himachal Pradesh, the company said. These batches were earlier shipped to the Gamaleya Centre in Russia for quality checks.
Sputnik V received emergency use authorisation in India in April this year. Sputnik V is a two-dose shot, which has been found to be 91.6% effective in preventing people from developing Covid-19.
So far, India has approved four vaccines — AstraZeneca and partner Serum Institute of India’s Covishield, Bharat Biotech’s Covaxin, Moderna’s shot and the Sputnik V.
Panacea Biotec began production of the vaccine in May, and the company plans to produce 100-million doses annually, RDIF said in April.
Would you like to comment on this article? Register (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Published by Arena Holdings and distributed with the Financial Mail on the last Thursday of every month except December and January.